Answers are grounded in this paper and cite their sources.
CD4+ T-cell enumeration remains critical for management of people with HIV (PWH). In resource-limited settings, point-of-care CD4 testing can increase accessibility and decrease turnaround time compared to flow cytometry. This study evaluated the performance of VITA™ point-of-care CD4 (Accesso Biotech; VITA™ CD4) compared to AQUIOS™ (Beckman Coulter; AQUIOS™) flow cytometry. Remnant venous blood samples from PWH with known CD4 counts on FDA-cleared AQUIOS™ flow cytometry were tested twice with VITA™ CD4. Statistical analyses included descriptive statistics, correlation analysis, Bland-Altman agreement analysis, and Passing-Bablok regression. The coefficient of variation was calculated on duplicate measurements. The University of San Francisco Institutional Review Board approved the study. VITA™ CD4 results showed strong correlation with AQUIOS flow cytometry (r = 0.973, p < 0.001). Bland-Altman analysis revealed a mean bias of -48.9 cells/μl (95% CI: -61.8 to -36.0), with limits of agreement from -231.1 to 133.3 cells/μl. For samples <500 CD4 cells/μL (n = 137), the mean bias was reduced to -8.6 cells/μl (95% CI: -17.8 to 0.6). Passing-Bablok regression suggested a small constant positive bias and proportional bias at counts above 500 cells/μl [y = 30.2 (95% CI: 19.3 to 44.2) + 0.83× (95% CI: 0.80-0.86)]. The coefficient of variation for duplicate VITA POC CD4 measurements was 11.86%. VITA™ CD4 results correlated strongly with flow cytometry at clinically relevant CD4 values. Its diagnostic performance and applicability at point-of-care make it a promising CD4 tool, also in settings with limited laboratory infrastructure. Further clinical validation and assessment of user acceptability is recommended.
No takes yet. Share an insight, caveat, or question.
Ong et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: